ADAP NY-ESO TCR: Phase I/II expanded

Adaptimmune expanded the open-label, U.S. Phase I/II study 04511 evaluating a single infusion of enhanced TCR therapy targeting NY-ESO-1 to include 2 additional cohorts of 10 patients each based on safety and efficacy data (see BioCentury, Oct. 20, 2014). The expansion also triggered 2 undisclosed milestone payments to Adaptimmune from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) under a 2014 deal granting GSK an exclusive option to license worldwide rights to the NY-ESO-1 therapy (see BioCentury, June 9, 2014). ...